ERBB2 and breast cancer: We have also demonstrated that low-titer HER2-specific antibodies induced by vaccinating breast cancer patients with a HER2 protein vaccine can bind to receptor and inhibit HER2 signaling through blocking tyrosine 877 phosphorylation of HER2, but did not induce receptor internalization and degradation.